Presentations
Home OCT Monitoring: The Future of AMD Management
Judy E. Kim, MDOut of 196 patients in the NOTAL-OCT V2.5 system performance and usability study, 90% could self-operate the device and capture gradable image of their macula. The study demonstrated that elderly patients with intermediate or advanced AMD can effectively self-operate an OCT and that they would consider using it to self-test at home. Home-based OCT testing has the potential to be an adjunct to in-office standard-of-care management and treatment of retinal vascular diseases.
Performance and Usability of a Self-operated Home OCT system
Judy E. Kim, MDOut of 196 patients in the NOTAL-OCT V2.5 system performance and usability study, 90% could self-operate the device and capture gradable image of their macula. The study demonstrated that elderly patients with intermediate or advanced AMD can effectively self-operate an OCT and that they would consider using it to self-test at home. Home-based OCT testing has the potential to be an adjunct to in-office standard-of-care management and treatment of retinal vascular diseases.
Comparison Between Retinal Images Captured by a Self-Operated, Home-based Optical Coherence Tomography (OCT) System and Commercial OCT Systems
Oren Tomkins-Netzer, MD, PhD & Michael J. Elman, MDThe majority of patients in the study were able to successfully self-operate the NOTAL-OCT V2.5 system and obtain OCT images of their own AMD affected eyes. Images captured using the patient self-operated NOTALOCT V2.5 demonstrated 92% sensitivity and 97% specificity to the technician-administered commercial OCT devices. This user-friendly OCT system designed for at-home, technician-free use has the potential to reach image sensitivity and specificity similar to a commercial OCT, and to support regularly scheduled standard-of-care clinical assessments and treatments by ophthalmic specialists.
Patient Experience Self-Operating an Optical Coherence Tomography (OCT) Device Developed for Home Use
Michael J. Elman, MDThe usability study demonstrates that elderly patients with intermediate or advanced AMD can effectively self-operate an OCT and that they would consider using it to self-test at home. This home-based OCT testing has the potential to be an adjunct to in-office standard-of-care management and treatment of retinal vascular diseases such as wet AMD, diabetic macular edema, and diabetic retinopathy.
Real-World Analysis of Injection Frequency Following Wet AMD Diagnosis According to Baseline Visual Acuity
Judy E. KimUndertreatment is a reality in clinical settings. The IRIS® Registry study demonstrated lower injection frequency in nAMD eyes compared to pivotal clinical trials. Undertreatment was regardless of baseline visual acuity (VA), first eye and/or second eye. The injection frequency was lower for the worst VA group for year 1 and year 2; and was lower in year 2 compared to year 1. Under treatment may result in less visual gain compared to the pivotal trials, and did not differ between the first and the second eyes diagnosed.